Filing Flows › Immucell (ICCC) › Capital expenditures
Immucell (ICCC) capital expenditures by quarter
Immucell's capital expenditures were $734K in Q2 2026 (second quarter 2026), +314% from Q1 2026. Over the last 5 quarters it ranged from $155K (Q2 2025) to $734K (Q2 2026).
| Quarter | Capital expenditures | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $734K | +314% | +373% |
| Q1 2026 | $177K | +3% | -46% |
| Q4 2025 | $172K | +11% | — |
| Q2 2025 | $155K | -53% | — |
| Q1 2025 | $329K | — | — |
Q2 2026 at a glance
Immucell, Q2 2026: revenue $7.2M (+12% year over year), operating margin 26.9%, net earnings $1.8M, operating cash flow $3.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is Immucell's capital expenditures?
Immucell's capital expenditures were $734K in Q2 2026 (second quarter 2026), +314% from Q1 2026.
How has Immucell's capital expenditures changed?
Over the last 5 quarters it ranged from $155K (Q2 2025) to $734K (Q2 2026).